GLP-1 Medications Associated with Fewer Psychiatric Hospitalizations for Schizophrenia Patients with Diabetes

Research in The Lancet Psychiatry found that GLP-1 receptor agonists are linked to lower risks of psychiatric hospitalization and emergency department visits for individuals with both schizophrenia and type 2 diabetes. An observational study of over 70,000 adults showed GLP-1 users were 24% less likely to need psychiatric admission, suggesting potential secondary mental health benefits for this vulnerable patient group beyond diabetes management.